Skip to Content

Onrigin Approval Status

  • FDA approved: No
  • Brand name: Onrigin
  • Generic name: laromustine
  • Dosage form: Injection
  • Company: Vion Pharmaceuticals, Inc.
  • Treatment for: Acute Myeloid Leukemia

Onrigin (laromustine), formerly known as Cloretazine (VNP40101M), is a novel alkylating agent in development for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).

Development Status and FDA Approval Process for Onrigin

Mar  1, 2010Vion Pharmaceuticals Receives Response From FDA on Special Protocol Assessment for Onrigin
Dec 14, 2009Vion Pharmaceuticals Receives Complete Response Letter for Onrigin From The U.S. Food And Drug Administration
Sep  2, 2009Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin
Aug 12, 2009Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin
Apr 23, 2009Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin
Apr 16, 2009Vion Pharmaceuticals' New Drug Application for Onrigin Accepted For Review by the FDA
Feb 17, 2009Vion Pharmaceuticals Submits New Drug Application for Onrigin

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.